Fig. 3

Pharmacodynamic Responses of BET Inhibitor Biomarkers in Peripheral Blood and Tumor Tissue: A. Quantification of CD14+/CD11b + monocyte populations in peripheral blood, illustrating changes from baseline (expressed as log2 fold-change from cycle onset) for individual patients (denoted as points), with longitudinal data from the same individual linked. Patients lacking baseline or sequential samples are excluded. Color highlights patients with partial response (purple), immune-mediated adverse events (orange), or systemic immune activation (red). Refer to (Fig. 1 for time point definitions. Boxplots depict median (center line), quartiles (box limits), and variability (whiskers extend to 1.5x interquartile range). B. Tumor expression levels of established BETi target genes, as determined by RNA-seq, indicating gene expression modifications (log2 fold-change) from the screening (pre-treatment) sample. Exclusions apply for participants without screening or on-treatment samples. The same color coding as in Panel A is used. C. Gene signature enrichment analysis reflecting BETi downstream effects, with heatmaps showcasing signature scores and gene expression alterations. Green and purple denote significantly up- or down-regulated signatures, respectively, with red and blue highlighting individual gene expression shifts within significant signatures. Asterisks indicate statistical significance. Time points align with those in Panel B